Catheter-related thrombosis in cancer patients: Pathophysiology, diagnosis, and management

Hematology/Oncology Clinics of North America

Volumn 19, Issue 1, 2005, Pages 183-202

  Rosovsky, Rachel P ^a   Kuter, David J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CAPECITABINE; CYTOCHROME P450; DALTEPARIN; ENOXAPARIN; FLUOROURACIL; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; VITAMIN K GROUP; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTICOAGULATION; ARTIFICIAL EMBOLISM; AUTOPSY; BLEEDING; CANCER PATIENT; CATHETER; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETERIZATION; CLINICAL PRACTICE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DRUG ANTAGONISM; DRUG EFFICACY; FIBRIN FORMATION; HUMAN; HYPERCOAGULABILITY; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS; PATHOPHYSIOLOGY; PHLEBITIS; PHLEBOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE; CATHETERIZATION; DISEASE MANAGEMENT; NEOPLASM; VEIN THROMBOSIS;

CATHETERIZATION; CATHETERIZATION, CENTRAL VENOUS; DISEASE MANAGEMENT; HUMANS; NEOPLASMS; VENOUS THROMBOSIS;

EID: 15544389977     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.09.007     Document Type: Review

References (100)

1. D.C. McGee, and M.K. Gould Preventing complications of central venous catheterization N Engl J Med 348 2003 1123 1133
2. A. Cadman, J.A. Lawrance, and L. Fitzsimmons To clot or not to clot? That is the question in central venous catheters Clin Radiol 59 2004 349 355
3. K.H. Polderman, and A.R. Girbes Central venous catheter use. Part 2: infectious complications Intensive Care Med 28 2002 18 28
4. R. Aubaniac The subclavian vein puncture-advantages and technique. 1952 Nutrition 6 1990 139 140 [discussion: 41]
5. R. Aubaniac [A new route for venous injection or puncture: the subclavicular route, subclavian vein, brachiocephalic trunk] Sem Hop 28 1952 3445 3447
6. R. Aubaniac [Subclavian intravenous injection: advantages and technique] Presse Med 60 1952 1456
7. R. Aubaniac [Subclavian intravenous transfusion: advantages and technique] Afr Francaise Chir 8 1952 131 135
8. J.W. Broviac, J.J. Cole, and B.H. Scribner A silicone rubber atrial catheter for prolonged parenteral alimentation Surg Gynecol Obstet 136 1973 602 606
9. R.O. Hickman, C.D. Buckner, and R.A. Clift A modified right atrial catheter for access to the venous system in marrow transplant recipients Surg Gynecol Obstet 148 1979 871 875
10. J.E. Niederhuber, W. Ensminger, and J.W. Gyves Totally implanted venous and arterial access system to replace external catheters in cancer treatment Surgery 92 1982 706 712
11. T. Bregenzer, D. Conen, and P. Sakmann Is routine replacement of peripheral intravenous catheters necessary? Arch Intern Med 158 1998 151 156
12. V.L. Hoshal Jr, R.G. Ause, and P.A. Hoskins Fibrin sleeve formation on indwelling subclavian central venous catheters Arch Surg 102 1971 253 258
13. L. Balestreri, M. De Cicco, and M. Matovic Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study Eur J Radiol 20 1995 108 111
14. M. De Cicco, M. Matovic, and L. Balestreri Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term Silastic catheter. A prospective study Thromb Res 86 1997 101 113
15. H. Starkhammar, M. Bengtsson, and O. Morales Fibrin sleeve formation after long term brachial catheterisation with an implantable port device. A prospective venographic study Eur J Surg 158 1992 481 484
16. I.I. Raad, D.C. Hohn, and B.J. Gilbreath Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion Infect Control Hosp Epidemiol 15 1994 231 238
17. I. Raad, W. Costerton, and U. Sabharwal Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement J Infect Dis 168 1993 400 407
18. J.H. Tenney, M.R. Moody, and K.A. Newman Adherent microorganisms on luminal surfaces of long-term intravenous catheters. Importance of Staphylococcus epidermidis in patients with cancer Arch Intern Med 146 1986 1949 1954
19. S. Ray, R. Stacey, and M. Imrie A review of 560 Hickman catheter insertions Anaesthesia 51 1996 981 985
20. R.E. Schwarz, D.G. Coit, and J.S. Groeger Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection Ann Surg Oncol 7 2000 441 449
21. A.J. Anderson, S.H. Krasnow, and M.W. Boyer Thrombosis: the major Hickman catheter complication in patients with solid tumor Chest 95 1989 71 75
22. M.R. Hurtibise, J.C. Bottino, and M. Lawson Restoring patency of occluded central venous catheters Arch Surg 115 1980 212 213
23. M. Lawson, J.C. Bottino, and M.R. Hurtibise The use of urokinase to restore patency of occluded central venous catheters Am J Intraven Ther Clin Nutr 9 1982 29 32
24. J.R. Gould, H.W. Carloss, and W.L. Skinner Groshong catheter-associated subclavian venous thrombosis Am J Med 95 1993 419 423
25. L.C. Stephens, W.D. Haire, and G.D. Kotulak Are clinical signs accurate indicators of the cause of central venous catheter occlusion? JPEN J Parenter Enteral Nutr 19 1995 75 79
26. P. Boraks, J. Seale, and J. Price Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies Br J Haematol 101 1998 483 486
27. K.M. Carr, and I. Rabinowitz Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors J Clin Oncol 18 2000 3665 3667
28. M.G. Conlan, W.D. Haire, and R.P. Lieberman Catheter-related thrombosis in patients with refractory lymphoma undergoing autologous stem cell transplantation Bone Marrow Transplant 7 1991 235 240
29. P.S. Craft, J. May, and A. Dorigo Hickman catheters: left-sided insertion, male gender, and obesity are associated with an increased risk of complications Aust N Z J Med 26 1996 33 39
30. M.A. de Gregorio, J.M. Miguelena, and J.A. Fernandez Subcutaneous ports in the radiology suite: an effective and safe procedure for care in cancer patients Eur Radiol 6 1996 748 752
31. M.E. Eastman, M. Khorsand, and D.G. Maki Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2 Cancer 91 2001 806 814
32. B.J. Eastridge, and A.T. Lefor Complications of indwelling venous access devices in cancer patients J Clin Oncol 13 1995 233 238
33. S.H. Goey, J. Verweij, and R.L. Bolhuis Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients Cancer Immunol Immunother 44 1997 301 304
34. W.D. Haire, J.A. Edney, and J.D. Landmark Thrombotic complications of subclavian apheresis catheters in cancer patients: prevention with heparin infusion J Clin Apheresis 5 1990 188 191
35. R. Knofler, E. Siegert, and I. Lauterbach Clinical importance of prothrombotic risk factors in pediatric patients with malignancy-impact of central venous lines Eur J Pediatr 158 Suppl 3 1999 S147 S150
36. V.A. Minassian, A.K. Sood, and P. Lowe Longterm central venous access in gynecologic cancer patients J Am Coll Surg 191 2000 403 409
37. C. Wermes, M. von Depka Prondzinski, and R. Lichtinghagen Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters Eur J Pediatr 158 Suppl 3 1999 S143 S146
38. D.C. Heaton, D.Y. Han, and A. Inder Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis Intern Med J 32 2002 84 88
39. A. Barzaghi, M. Dell'Orto, and A. Rovelli Central venous catheter clots: incidence, clinical significance and catheter care in patients with hematologic malignancies Pediatr Hematol Oncol 12 1995 243 250
40. M.M. Bern, J.J. Lokich, and S.R. Wallach Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial Ann Intern Med 112 1990 423 428
41. M. De Cicco, M. Matovic, and L. Balestreri Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients Thromb Res 78 1995 127 137
42. D.W. Glaser, D. Medeiros, and N. Rollins Catheter-related thrombosis in children with cancer J Pediatr 138 2001 255 259
43. M.K. Horne III, P.K. Merryman, and D.J. Mayo Reductions in tissue plasminogen activator and thrombomodulin in blood draining veins damaged by venous access devices Thromb Res 79 1995 369 376
44. M.K. Horne III, D.J. Mayo, and H.R. Alexander Upper extremity impedance plethysmography in patients with venous access devices Thromb Haemost 72 1994 540 542
45. M. Monreal, A. Alastrue, and M. Rull Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin) Thromb Haemost 75 1996 251 253
46. A. Pucheu, B. Leduc, and I. Sillet-Bach Experimental prevention of deep venous thrombosis with low-molecular-weight heparin using implantable infusion devices Ann Cardiol Angeiol (Paris) 45 1996 59 63
47. I.I. Raad, M. Luna, and S.A. Khalil The relationship between the thrombotic and infectious complications of central venous catheters JAMA 271 1994 1014 1016
48. P. Reichardt, A. Kretzschmar, and M. Biakhov A phase III randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, Fragmin) in preventing catheter-related complications (CRCs) in cancer patients with central venous catheter (CVCs) Proc Am Soc Clin Oncol 21 2002 369a
49. M.K. Horne III, D.J. May, and H.R. Alexander Venographic surveillance of tunneled venous access devices in adult oncology patients Ann Surg Oncol 2 1995 174 178
50. I. Curelaru, A. Bylock, and B. Gustavsson Dynamics of thrombophlebitis in central venous catheterization via basilic and cephalic veins Acta Chir Scand 150 1984 285 293
51. J.J. Lokich, and B. Becker Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy Cancer 52 1983 1586 1589
52. O.W. Press, P.G. Ramsey, and E.B. Larson Hickman catheter infections in patients with malignancies Medicine (Baltimore) 63 1984 189 200
53. K.J. Henrickson, R.A. Axtell, and S.M. Hoover Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial J Clin Oncol 18 2000 1269 1278
54. P.L. Massoure, J. Constans, and M. Caudry Upper extremity deep venous thrombosis: 40 hospitalized patients J Mal Vasc 25 2000 250 255
55. P. Prandoni, P. Polistena, and E. Bernardi Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications Arch Intern Med 157 1997 57 62
56. M. Monreal, E. Lafoz, and J. Ruiz Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study Chest 99 1991 280 283
57. M. Monreal, and E. Davant Thrombotic complications of central venous catheters in cancer patients Acta Haematol 106 2001 69 72
58. S.S. Durica Venous thromboembolism in the cancer patient Curr Opin Hematol 4 1997 306 311
59. A. Letai, and D.J. Kuter Cancer, coagulation, and anticoagulation Oncologist 4 1999 443 449
60. P. Prandoni, A. Piccioli, and A. Girolami Cancer and venous thromboembolism: an overview Haematologica 84 1999 437 445
61. M. Valente, and E. Ponte Thrombosis and cancer Minerva Cardioangiol 48 2000 117 127
62. F.W. Leebeek, N.A. Stadhouders, and D. van Stein Hypercoagulability states in upper-extremity deep venous thrombosis Am J Hematol 67 2001 15 19
63. W.D. Haire, R.P. Lieberman, and J. Edney Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation Cancer 66 1990 900 908
64. C.E. Nightingale, A. Norman, and D. Cunningham A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy Eur J Cancer 33 1997 398 403
65. G.V. Stanislav, R.J. Fitzgibbons Jr, and R.T. Bailey Jr Reliability of implantable central venous access devices in patients with cancer Arch Surg 122 1987 1280 1283
66. J.K. Brown-Smith, M.H. Stoner, and Z.A. Barley Tunneled catheter thrombosis: factors related to incidence Oncol Nurs Forum 17 1990 543 549
67. B.O. Mustafa, S.W. Rathbun, and T.L. Whitsett Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review Arch Intern Med 162 2002 401 404
68. C. Koksoy, A. Kuzu, and J. Kutlay The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis Clin Radiol 50 1995 687 689
69. P. Chait, M. Dinyari, and P. Massicote The sensitivity and specificity of linegrams and ultrasound compared with venography for the diagnosis of central venous line related thrombosis in symptomatic children: The LUV Study Thromb Haemost 2001 P697
70. W.D. Haire, T.G. Lynch, and G.B. Lund Limitations of magnetic resonance imaging and ultrasound-directed (duplex) scanning in the diagnosis of subclavian vein thrombosis J Vasc Surg 13 1991 391 397
71. G. Forneris, F. Quarello, and M. Pozzato [Spiral x-ray computed tomography in the diagnosis of central venous catheterization complications] Nephrologie 22 2001 495 499
72. K.J. Savage, P.S. Wells, and V. Schulz Outpatient use of low molecular weight heparin (dalteparin) for the treatment of deep vein thrombosis of the upper extremity Thromb Haemost 82 1999 1008 1010
73. A.Y. Lee, M.N. Levine, and R.I. Baker Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146 153
74. L.D. Spence, M.G. Gironta, and H.M. Malde Acute upper extremity deep venous thrombosis: safety and effectiveness of superior vena caval filters Radiology 210 1999 53 58
75. D. Ponec, D. Irwin, and W.D. Haire Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial-the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial J Vasc Interv Radiol 12 2001 951 955
76. A.K.C. Chan, Y.J. Du, and L.R. Berry Covalent antithrombin-heparin complex coated catheter prevents thrombosis in a rabbit central venous catheter model Thromb Haemost 86 Suppl 1 2001 310S
77. L.C. Stephens, W.D. Haire, and S. Tarantolo Normal saline versus heparin flush for maintaining central venous catheter patency during apheresis collection of peripheral blood stem cells (PBSC) Transfus Sci 18 1997 187 193
78. A.G. Randolph, D.J. Cook, and C.A. Gonzales Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials Chest 113 1998 165 171
79. W.H. Geerts, J.A. Heit, and G.P. Clagett Prevention of venous thromboembolism Chest 119 2001 132S 175S
80. G. Guyatt, H. Schunemann, and D. Cook Grades of recommendation for antithrombotic agents Chest 119 2001 3S 7S
81. J. Hirsh, J. Dalen, and G. Guyatt The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians Chest 119 2001 1S 2S
82. M. Magagnoli, G. Masci, and C. Carnaghi Minidose warfarin is associated with a high incidence of international normalized ratio elevation during chemotherapy with FOLFOX regimen Ann Oncol 14 2003 959 960
83. G. Masci, M. Magagnoli, and P.A. Zucali Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 21 2003 736 739
84. M.C. Brown An adverse interaction between warfarin and 5-fluorouracil: a case report and review of the literature Chemotherapy 45 1999 392 395
85. Q. Zhou, and E. Chan Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats Eur J Pharm Sci 17 2002 73 80
86. J.M. Kolesar, C.L. Johnson, and B.L. Freeberg Warfarin-5-FU interaction-a consecutive case series Pharmacotherapy 19 1999 1445 1449
87. M.S. Copur, P. Ledakis, and M. Bolton An adverse interaction between warfarin and capecitabine: a case report and review of the literature Clin Colorectal Cancer 1 2001 182 184
88. B. Reigner, K. Blesch, and E. Weidekamm Clinical pharmacokinetics of capecitabine Clin Pharmacokinet 40 2001 85 104
89. W.H. Geerts, G.F. Pineo, and J.A. Heit Prevention of venous thromboembolism Chest 126 2004 338S 400S
90. A.G. Turpie, K.A. Bauer, and B.I. Eriksson Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies Arch Intern Med 162 2002 1833 1840
91. B.I. Eriksson, K.A. Bauer, and M.R. Lassen Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery N Engl J Med 345 2001 1298 1304
92. H. Eriksson, K. Wahlander, and D. Gustafsson A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis. THRIVE I J Thromb Haemost 1 2003 41 47
93. K.A. Bauer, B.I. Eriksson, and M.R. Lassen Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery N Engl J Med 345 2001 1305 1310
94. K.A. Bauer Fondaparinux sodium: a selective inhibitor of factor Xa Am J Health Syst Pharm 58 Suppl 2 2001 S14 S17
95. Idraparinux Sodium. SANORG 34006, SR 34006 Drugs R D 5 2004 164 165
96. C.W. Colwell, S.D. Berkowitz, and B.L. Davidson Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study J Thromb Haemost 1 2003 2119 2130
97. D. Gustafsson Oral direct thrombin inhibitors in clinical development J Intern Med 254 2003 322 334
98. J.L. Halperin Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V) Am Heart J 146 2003 431 438
99. P. de Moerloose, and F. Boehlen Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia Can J Anaesth 49 2002 S5 S10
100. B.I. Eriksson, and M.R. Lassen Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study Arch Intern Med 163 2003 1337 1342